Organization
The Medicines Co.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
The Medicines Co.
... Santhera Pharmaceuticals Holding AG / UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone(R) (idebenone) in Duchenne Muscular Dystrophy . ...
... redistribution of the UK's centrally authorised product portfolio for human and veterinary medicines. Re-allocation of over 370 products to new (co-) rapporteurs from the EU27 ...
... 2012, and Albireo was granted access in 2016 to the EMA's PRIority MEdicines (PRIME) program for the treatment of PFIC. PFIC is estimated to affect ...
... today announced the European Medicines Agency (EMA) has granted dilanubicel (NLA101) PRIority MEdicines (PRIME) designation for the treatment of patients receiving a Hematopoietic Stem Cell ...
... and European Union, and has been granted access to the EMA's PRIority MEdicines (PRIME) program for the treatment of PFIC. About the A50 Phase 3 ...
... PARSIPPANY - The Medicines Company (NASDAQ: MDCO) today announced that the results of a pre-specified analysis of ...
... Geneva - The Medicines Patent Pool (MPP) today announced five new generic manufacturing partners including ...
... The Medicines Company (NASDAQ:MDCO) today announced that the results of a pre-specified analysis of ...
... Twenty-fiveproduct developersnow working with the MPPtomanufacturelow-cost, quality-assuredtreatmentsfordeveloping countries The Medicines Patent Pool (MPP) today announced five new generic manufacturing partners including ...
Subscribe now for full coverage on The Medicines Co.
Start My Free Trial